Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Early Chronic Phase CML
NCT01535391Phase 3Completed
- Sponsor
- GIMEMA
- Start
- Jan 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by GIMEMA. Primary endpoint: Complete Molecular Response at 24 months. Started Jan 2012; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01535391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01535391.